SCHEMBL1327434

SCHEMBL1327434

CC(=O)CCCCC(N)=O

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 5/20 0.62
ALDH1A1 P00352 2/20 0.53
ACHE P22303 2/20 0.48
SOAT1 P35610 2/20 0.44
MEN1 O00255 1/20 0.44
FAAH O00519 1/20 0.44
TP53 P04637 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 1/20 0.44
LMNA P02545 3/20 0.43
SLC15A2 Q16348 1/20 0.43
ALOX15 P16050 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
KDM4E B2RXH2 2/20 0.40
TDP1 Q9NUW8 1/20 0.37
CNR1 P21554 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22423301 0.97 PAOX (0.67) PAOXALDH1A1ACHESOAT1MEN1
SCHEMBL30628038 0.97 PAOX (0.67) PAOXALDH1A1ACHESOAT1MEN1
SCHEMBL12488391 0.97 PAOX (0.67) PAOXALDH1A1ACHESOAT1MEN1
SCHEMBL1326327 0.97 PAOX (0.67) PAOXALDH1A1ACHESOAT1MEN1
SCHEMBL9410599 0.97 PAOX (0.67) PAOXALDH1A1ACHESOAT1MEN1
SCHEMBL23352440 0.97 PAOX (0.67) PAOXALDH1A1ACHESOAT1MEN1
SCHEMBL3318564 0.97 PAOX (0.67) PAOXALDH1A1ACHESOAT1MEN1
SCHEMBL9410608 0.97 PAOX (0.67) PAOXALDH1A1ACHESOAT1MEN1
SCHEMBL1326107 0.94
Acetic Acid SCHEMBL28338186 0.92 PAOX (0.61) PAOXALDH1A1ACHESOAT1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 US claimed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US claimed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP claimed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP claimed
EP-1660507-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-05-31 EP claimed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 US claimed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 WO claimed
US-11479574-B2 Vaccine against Klebsiella pneumoniae IDORSIA PHARMACEUTICALS LTD (CH) 2022-10-25 US disclosed
WO-2022079031-A1 REACTIVE CONJUGATES DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) 2022-04-21 WO disclosed
EP-3955964-A1 COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY Avidea Technologies, Inc. (US) 2022-02-23 EP disclosed
EP-3865552-A1 HEAT-TRANSFER FLUID WITH LOW CONDUCTIVITY COMPRISING AN AMIDE INHIBITOR, METHODS FOR ITS PREPARATION AND USES THEREOF Arteco NV (BE) 2021-08-18 EP disclosed
WO-2020247297-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2020-12-10 WO disclosed
WO-2020214858-A1 COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY AVIDEA TECHNOLOGIES, INC. (US) 2020-10-22 WO disclosed
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 US disclosed
WO-2011042450-A1 CARRIER LINKED PALIPERIDONE PRODRUGS ASCENDIS PHARMA AS (DK) 2011-04-14 WO disclosed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP disclosed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 PAOX 1819/4885ALDH1A1 3935/4885ACHE 3592/4885
US-11479574-B2 Vaccine against Klebsiella pneumoniae SLC11A2, OSTC, STT3A PAOX 1062/4885ALDH1A1 3833/4885ACHE 1214/4885
US-20050107307-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 PAOX 1819/4885ALDH1A1 3935/4885ACHE 3592/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 PAOX 1819/4885ALDH1A1 3935/4885ACHE 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.